The combination of Tarceva and Nexavar tablets to treat liver cancer didn't improve survival...


The combination of Tarceva and Nexavar tablets to treat liver cancer didn't improve survival rates compared with Nexavar on its own in a Phase III trial. Nexavar is jointly produced by Bayer and Onyx (ONXX -0.45%), while Tarceva, which is already used in lung cancer, is sold by Astellas Pharma and Roche unit Genentech.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs